Difference between revisions of "ICRP Glossary"

From ICRPaedia
Jump to navigation Jump to search
 
(54 intermediate revisions by the same user not shown)
Line 8: Line 8:
 
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.
 
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.
  
−
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
+
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in [[ICRP publications]].
  
 
----
 
----
 
{| class="wikitable"
 
{| class="wikitable"
 
|-
 
|-
−
| [[#A|A]] || [[#B|B]]  || [[#C|C]]|| [[#D|D]] || [[#E|E]] || [[#F|F]] || [[#G|G]] || [[#H|H]] || [[#I|I]] || [[#J|J]] || [[#K|K]] || [[#L|L]] || [[#M|M]] ||[[#N|N]] || [[#O|O]] || [[#P|P]] || [[#Q|Q]] || [[#R|R]] || [[#S|S]] || [[#T|T]] || [[#U|U]] || [[#V|V]] || [[#W|W]] || [[#X|X]] || [[#Y|Y]] || [[#Z|Z]] || [[#ZZ|...]]
+
| [[#09|0-9]] || [[#A|A]] || [[#B|B]]  || [[#C|C]]|| [[#D|D]] || [[#E|E]] || [[#F|F]] || [[#G|G]] || [[#H|H]] || [[#I|I]] || [[#J|J]] || [[#K|K]] || [[#L|L]] || [[#M|M]] ||[[#N|N]] || [[#O|O]] || [[#P|P]] || [[#Q|Q]] || [[#R|R]] || [[#S|S]] || [[#T|T]] || [[#U|U]] || [[#V|V]] || [[#W|W]] || [[#X|X]] || [[#Y|Y]] || [[#Z|Z]] || [[#ZZ|...]]
 
|}
 
|}
  
 
<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2">
 
<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2">
 +
 +
=== <big><span id="09">0-9</span></big> ===
 +
 +
*4DCT (see [[Time-resolved computed tomography]])
  
 
=== <big><span id="A">A</span></big> ===
 
=== <big><span id="A">A</span></big> ===
Line 35: Line 39:
  
 
*[[Accountability]]
 
*[[Accountability]]
 +
 +
*[[Accreditation]]
  
 
*[[Action Level]]
 
*[[Action Level]]
  
 
*[[Activation]]
 
*[[Activation]]
 +
 +
*[[Active detection system]]
  
 
*[[Active (red) bone marrow]]
 
*[[Active (red) bone marrow]]
Line 51: Line 59:
  
 
*[[Acute radiation syndrome]]
 
*[[Acute radiation syndrome]]
 +
 +
*[[Additional dose]]
  
 
*[[Adaptive response]]
 
*[[Adaptive response]]
  
 
*[[Additive risk projection model]]
 
*[[Additive risk projection model]]
 +
 +
*[[Adenoma]]
  
 
*[[Adventitious]]
 
*[[Adventitious]]
Line 62: Line 74:
 
*[[Aerodynamic diameter ]]
 
*[[Aerodynamic diameter ]]
  
−
*[[Air-kerma rate constant ]]
+
*[[Air-kerma rate constant]]
 +
 
 +
*[[Air kerma at the patient entrance reference point]]
  
 
*[[Air-kerma, entrance surface]]
 
*[[Air-kerma, entrance surface]]
Line 69: Line 83:
  
 
*[[Air-kerma, product]]
 
*[[Air-kerma, product]]
 +
 +
*[[ALARA]]
  
 
*ALI (see [[Annual limit on intake]])
 
*ALI (see [[Annual limit on intake]])
Line 75: Line 91:
  
 
*[[Alimentary tract transfer factor]]
 
*[[Alimentary tract transfer factor]]
 +
 +
*[[Allometry]]
  
 
*[[Alpha decay]]
 
*[[Alpha decay]]
Line 83: Line 101:
  
 
*[[Ambient dose equivalent]], H*(10)
 
*[[Ambient dose equivalent]], H*(10)
 +
 +
*[[AML/eto]]
  
 
*[[Angiogenesis]]
 
*[[Angiogenesis]]
Line 93: Line 113:
  
 
*[[Annual limit on intake]]
 
*[[Annual limit on intake]]
 +
 +
*[[Apoptosis]]
  
 
*[[Area monitoring]]
 
*[[Area monitoring]]
Line 109: Line 131:
  
 
*[[Autoimmune disease]]
 
*[[Autoimmune disease]]
 +
 +
*[[Automatic exposure control]]
  
 
*[[Autonomy]]
 
*[[Autonomy]]
Line 117: Line 141:
  
 
*[[Background dose (rate)]]
 
*[[Background dose (rate)]]
 +
 +
*[[Backscatter detection system]]
  
 
*[[Backscatter factor]]
 
*[[Backscatter factor]]
Line 125: Line 151:
  
 
*BAT (see [[Best available techniques]])
 
*BAT (see [[Best available techniques]])
 +
 +
*Bcr/abl (see [[Breakpoint cluster region/abelson]])
  
 
*[[Beneficence]]
 
*[[Beneficence]]
Line 149: Line 177:
  
 
*[[Bradycardia]]
 
*[[Bradycardia]]
 +
 +
*[[Brachytherapy]]
  
 
*[[Branching fraction]]
 
*[[Branching fraction]]
 +
 +
*[[Bragg peak]]
 +
 +
*[[Breakpoint cluster region/abelson]]
 +
 +
*[[Broad beam therapy irradiation technique]]
  
 
*[[Bronchial region]]
 
*[[Bronchial region]]
Line 159: Line 195:
  
 
=== <big><span id="C">C</span></big> ===
 
=== <big><span id="C">C</span></big> ===
 +
 +
*CACA (see [[Cobblestone area forming cell assay]])
 +
 +
*CAFC (see [[Cobblestone area forming cell assay]])
 +
 +
*CBCT (see [[Cone beam computed tomography]])
  
 
*[[Cardiac arrhythmias]]
 
*[[Cardiac arrhythmias]]
Line 167: Line 209:
  
 
*[[Cardioverter-defibrillator]]
 
*[[Cardioverter-defibrillator]]
 +
 +
*[[Carers and comforters]]
  
 
*[[Case–control study]]
 
*[[Case–control study]]
Line 181: Line 225:
  
 
*[[Class SR-2 gases]]
 
*[[Class SR-2 gases]]
 +
 +
*[[Clearance]]
  
 
*[[Clearance level]]
 
*[[Clearance level]]
 +
 +
*[[Clinical audit]]
  
 
*[[Clonogenic cells]]
 
*[[Clonogenic cells]]
  
 
*[[Clonogenic survival]]
 
*[[Clonogenic survival]]
 +
 +
*[[Clonogenic surviving fraction]]
 +
 +
*Cobblestone area cell assay (see [[Cobblestone area forming cell assay]])
 +
 +
*[[Cobblestone area forming cell assay]]
 +
 +
*[[Collective dose]]
  
 
*[[Co-expertise]]
 
*[[Co-expertise]]
Line 194: Line 250:
 
*[[Collective dose]]
 
*[[Collective dose]]
  
−
*[[Collective effective dose]], S
+
*[[Collective effective dose]]
 +
 
 +
*[[Collimation]]
  
 
*[[Colony]]
 
*[[Colony]]
 +
 +
*[[Commissioning]]
  
 
*[[Committed effective dose]]
 
*[[Committed effective dose]]
Line 203: Line 263:
  
 
*[[Compartment]]
 
*[[Compartment]]
 +
 +
*[[Compartment (environmental)]]
  
 
*[[Complex tissues]]
 
*[[Complex tissues]]
  
 
*[[Computed tomography dose index]]
 
*[[Computed tomography dose index]]
 +
 +
*[[Concentration ratio]]
 +
 +
*[[Cone beam computed tomography]]
  
 
*[[Connective tissue]]
 
*[[Connective tissue]]
Line 213: Line 279:
  
 
*[[Constancy test]]
 
*[[Constancy test]]
 +
 +
*[[Containment]]
  
 
*[[Contamination]]
 
*[[Contamination]]
  
 
*[[Coronary heart disease]]
 
*[[Coronary heart disease]]
 +
 +
*[[Cosmic radiation]]
  
 
*[[Cost-benefit analysis]]
 
*[[Cost-benefit analysis]]
  
 
*[[Coster-Kronig transition]]
 
*[[Coster-Kronig transition]]
 +
 +
*CR (see [[Concentration ratio]])
  
 
*[[Cross section]]
 
*[[Cross section]]
 +
 +
*Cumulative air kerma (see [[Air kerma at the patient entrance reference point]])
  
 
*[[Cumulative dose]]
 
*[[Cumulative dose]]
Line 233: Line 307:
  
 
*DAC (see [[Derived air concentration]])
 
*DAC (see [[Derived air concentration]])
 +
 +
*DBT (see [[Digital breast tomosynthesis]])
 +
 +
*DCRL (see [[Derived consideration reference level]])
  
 
*DD (see [[Doubling dose]])
 
*DD (see [[Doubling dose]])
 +
 +
*DDI, detector dose indicator (see [[Exposure index]])
  
 
*DIL (see [[Derived investigation level]])
 
*DIL (see [[Derived investigation level]])
Line 247: Line 327:
  
 
*[[Decontamination factor]]
 
*[[Decontamination factor]]
 +
 +
*[[Dental and maxillofacial imaging]]
  
 
*[[Deontological Ethics]]
 
*[[Deontological Ethics]]
  
−
*[[Deposition]]
+
*[[Deposition]] (inhalation)
  
 
*[[Derived air concentration]]
 
*[[Derived air concentration]]
 +
 +
*[[Derived consideration reference level]]
  
 
*[[Derived investigation level]]  
 
*[[Derived investigation level]]  
 +
 +
*[[Derived limit]]
 +
 +
*[[Derived reference level]]
 +
 +
*[[Designated area]]
 +
 +
*Detector dose indicator (see [[Exposure index]])
 +
 +
*[[Detector quantum efficiency]]
  
 
*[[Deterministic effect]]
 
*[[Deterministic effect]]
Line 261: Line 355:
  
 
*[[Detriment-adjusted risk]]
 
*[[Detriment-adjusted risk]]
 +
 +
*[[Diagnostic reference level]]
  
 
*[[Diastasis]]
 
*[[Diastasis]]
Line 269: Line 365:
  
 
*[[Differentiation]]
 
*[[Differentiation]]
 +
 +
*[[Digital breast tomosynthesis]]
  
 
*[[Dignity]]
 
*[[Dignity]]
Line 281: Line 379:
  
 
*[[Distribution coefficient]] (''K<sub>d</sub>'')
 
*[[Distribution coefficient]] (''K<sub>d</sub>'')
 +
 +
*DLP (see [[Dose-length product]])
  
 
*[[DNA damage signalling]]
 
*[[DNA damage signalling]]
Line 302: Line 402:
 
*[[Dose criteria]]
 
*[[Dose criteria]]
  
−
*[[Dose of record (E)]]
+
*[[Dose equivalent]] in an organ or tissue
−
 
 
−
*[[Dose of record H<sub>p</sub> (10)]]
 
−
 
 
−
*[[Dose equivalent in an organ or tissue]]
 
  
 
*[[Dose limit]]
 
*[[Dose limit]]
  
 
*[[Dose modifying factor]]
 
*[[Dose modifying factor]]
 +
 +
*[[Dose of record (E)]]
 +
 +
*[[Dose of record Hp (10)]]
  
 
*[[Dose per content function]]
 
*[[Dose per content function]]
Line 319: Line 419:
  
 
*[[Dose rate effectiveness factor]]
 
*[[Dose rate effectiveness factor]]
 +
 +
*[[Dose-length product]]
  
 
*[[Dose-threshold hypothesis]]
 
*[[Dose-threshold hypothesis]]
Line 324: Line 426:
 
*[[Dose-rate effect]]
 
*[[Dose-rate effect]]
  
−
*[[Dose–response function ]]
+
*[[Dose-response function]]
  
 
*[[Dose-threshold]]
 
*[[Dose-threshold]]
  
 
*[[Doubling dose]]
 
*[[Doubling dose]]
 +
 +
*DQE (see [[Detector quantum efficiency]])
 +
 +
*DRL (see [[Diagnostic reference level]])
 +
 +
*[[DRL process]]
 +
 +
*[[DRL quantity]]
 +
 +
*[[DRL value]]
  
 
*[[DS02]]
 
*[[DS02]]
Line 347: Line 459:
  
 
*[[Effective charge number]]
 
*[[Effective charge number]]
 +
 +
*[[Effective dose]], E
  
 
*[[Effective dose equivalent]]
 
*[[Effective dose equivalent]]
  
 
*[[Effective half-life]]
 
*[[Effective half-life]]
 +
 +
*EI (see [[Exposure index]])
  
 
*[[Electron-capture decay]]
 
*[[Electron-capture decay]]
Line 369: Line 485:
  
 
*[[Emergency procedures]]
 
*[[Emergency procedures]]
 +
 +
*[[Employer]]
  
 
*[[Endogeneous excretion]]
 
*[[Endogeneous excretion]]
  
−
*[[Epigenetic effects]]
+
*Endosteal tissue (see [[Endosteum]])
 +
 
 +
*[[Endosteum]]  
  
 
*[[Environmental exposure]]
 
*[[Environmental exposure]]
  
 
*[[Environmental radiation protection]]
 
*[[Environmental radiation protection]]
 +
 +
*[[Epigenetic effects]]
  
 
*[[Epithelium]]
 
*[[Epithelium]]
 +
 +
*[[Equieffective dose]]
 +
 +
*[[Equilibrium equivalent concentration]]
 +
 +
*[[Equilibrium factor]]
  
 
*[[Equity]]
 
*[[Equity]]
Line 389: Line 517:
  
 
*[[Ethics]]
 
*[[Ethics]]
 +
 +
*[[Evacuation]]
  
 
*[[Excess absolute risk]]
 
*[[Excess absolute risk]]
Line 397: Line 527:
  
 
*[[Excretion rate (instantaneous)]]
 
*[[Excretion rate (instantaneous)]]
 +
 +
*[[Exclusion]]
  
 
*[[Exempt waste]]
 
*[[Exempt waste]]
Line 403: Line 535:
  
 
*[[Existing exposure situation]]
 
*[[Existing exposure situation]]
 +
 +
*[[Exogenous excretion]]
 +
 +
*[[Expanded and aligned radiation field]]
 +
 +
*[[Expanded radiation field]]
  
 
*[[Exponential survival curve]]
 
*[[Exponential survival curve]]
 +
 +
*[[Exposed individuals]]
  
 
*[[Exposure, external or internal]]
 
*[[Exposure, external or internal]]
 +
 +
*[[Exposure (in the context of inhalation)]]
 +
 +
*[[Exposure index]]
  
 
*[[Exposure pathway]]
 
*[[Exposure pathway]]
Line 421: Line 565:
  
 
*[[Flexible tissues]]
 
*[[Flexible tissues]]
 +
 +
*[[Fluence]], Φ
  
 
*[[Fluoroscopically guided interventions]]
 
*[[Fluoroscopically guided interventions]]
 +
 +
*[[Fluoroscopically or computed tomography guided interventions]]
  
 
*[[Forbiddenness]]
 
*[[Forbiddenness]]
 +
 +
*[[Fractional absorption in the gastrointestinal tract]], f<sub>1</sub>
  
 
*[[Fractionation]]
 
*[[Fractionation]]
 +
 +
*[[Fractionation and dose delivery patterns]]
  
 
*[[Fractionation sensitivity]]
 
*[[Fractionation sensitivity]]
 +
 +
*[[Frequent flyer]]
 +
 +
*FSU (see [[Functional subunits]])
 +
 +
*[[Functional subunits]]
  
 
=== <big><span id="G">G</span></big> ===
 
=== <big><span id="G">G</span></big> ===
Line 437: Line 595:
  
 
*[[Gastrointestinal syndrome]]
 
*[[Gastrointestinal syndrome]]
 +
 +
*[[Gastrulation]]
 +
 +
*[[Gastroschisis]]
 +
 +
*[[GATA binding protein 2]]
 +
 +
*GATA-2 (see [[GATA binding protein 2]])
  
 
*[[Genomic integrity]]
 
*[[Genomic integrity]]
 +
 +
*Geomagnetic cut-off rigidity (see [[Rigidity threshold]])
  
 
*[[Graded approach]]
 
*[[Graded approach]]
 +
 +
*[[Graft vs host disease]]
  
 
*[[Granulocyte colony-stimulating factor]]
 
*[[Granulocyte colony-stimulating factor]]
  
 
*[[Granulocyte-macrophage colony-stimulating factor]]
 
*[[Granulocyte-macrophage colony-stimulating factor]]
 +
 +
*[[Gray]] (Gy)
 +
 +
*[[Ground-level enhancement]]
 +
 +
*[[Growth factor]]
  
 
*[[Growth fraction]]
 
*[[Growth fraction]]
Line 457: Line 633:
  
 
*[[Half-life, physical]]
 
*[[Half-life, physical]]
 +
 +
*HATM (see [[Human Alimentary Tract Model]])
  
 
*[[Hazard]]
 
*[[Hazard]]
Line 469: Line 647:
  
 
*[[High level waste]]
 
*[[High level waste]]
 +
 +
*[[High linear energy transfer radiation]]
  
 
*[[Homologous recombination]]
 
*[[Homologous recombination]]
Line 474: Line 654:
 
*[[Hormones]]
 
*[[Hormones]]
  
−
*[[Human respiratory tract model]]
+
*[[Hounsfield unit]]
 +
 
 +
*HRTM (see [[Human Respiratory Tract Model]])
 +
 
 +
*[[Human Alimentary Tract Model]]
 +
 
 +
*[[Human Respiratory Tract Model]]
  
 
*[[Hyperbaric oxygen]]
 
*[[Hyperbaric oxygen]]
 +
 +
*[[Hyperfractionation]]
  
 
*[[Hypertrophic cardiomyopathy]]
 
*[[Hypertrophic cardiomyopathy]]
Line 483: Line 671:
  
 
=== <big><span id="I">I</span></big> ===
 
=== <big><span id="I">I</span></big> ===
 +
 +
*[[ICRU 4-element tissue]]
 +
 +
*[[ICRU sphere]]
  
 
*[[Immune system]]
 
*[[Immune system]]
 +
 +
*IMRT (see [[Intensity-modulated radiotherapy]])
  
 
*[[In vivo radiobioassay]]
 
*[[In vivo radiobioassay]]
Line 511: Line 705:
  
 
*[[Institutional control]]
 
*[[Institutional control]]
 +
 +
*[[Intervention]]
 +
 +
*[[Intensity-modulated radiotherapy]]
 +
 +
*[[Intake]]
  
 
*[[Intermediate level waste]]
 
*[[Intermediate level waste]]
Line 539: Line 739:
  
 
=== <big><span id="K">K</span></big> ===
 
=== <big><span id="K">K</span></big> ===
 +
 +
*[[Kerma]], K
 +
 +
*[[Kerma approximation]]
  
 
*[[Kp index]]
 
*[[Kp index]]
  
 
=== <big><span id="L">L</span></big> ===
 
=== <big><span id="L">L</span></big> ===
 +
 +
*[[Lag]]
  
 
*[[Late normal tissue responses]]
 
*[[Late normal tissue responses]]
Line 549: Line 755:
  
 
*[[LD 50/30|LD<sub>50/30</sub>]]
 
*[[LD 50/30|LD<sub>50/30</sub>]]
 +
 +
*LET (see [[Linear energy transfer]])
 +
 +
*[[Licensee]]
  
 
*[[Life Span Study]]
 
*[[Life Span Study]]
Line 561: Line 771:
  
 
*[[Linear dose response]]
 
*[[Linear dose response]]
 +
 +
*[[Linear energy transfer]]
  
 
*[[Linear-non-threshold model]]
 
*[[Linear-non-threshold model]]
Line 567: Line 779:
  
 
*LLE (see [[Lifetime risk estimates]])
 
*LLE (see [[Lifetime risk estimates]])
 +
 +
*[[Local DRL]]
  
 
*Loss of Life Expectancy (see [[Lifetime risk estimates]])
 
*Loss of Life Expectancy (see [[Lifetime risk estimates]])
Line 577: Line 791:
  
 
*[[Low level waste]]
 
*[[Low level waste]]
 +
 +
*[[Low linear energy transfer radiation]]
  
 
*LSS (see [[Life Span Study]])
 
*LSS (see [[Life Span Study]])
Line 587: Line 803:
  
 
*[[Magnetosphere]]
 
*[[Magnetosphere]]
 +
 +
*[[Marrow cellularity]]
 +
 +
*[[Mass median diameter]]
 +
 +
*MDCT (see [[Multi-detector computed tomography]])
 +
 +
*[[Mean glandular dose]]
 +
 +
*[[Measured quantity]]
  
 
*[[Medical exposure]]
 
*[[Medical exposure]]
Line 595: Line 821:
  
 
*[[Mitigation]]
 
*[[Mitigation]]
 +
 +
*MMD (see [[Mass median diameter]])
 +
 +
*[[Molecular imaging]]
 +
 +
*[[Multifactorial diseases]]
  
 
*[[Multiplicative risk projection model]]
 
*[[Multiplicative risk projection model]]
Line 601: Line 833:
  
 
*[[Multistage tumorigenesis]]
 
*[[Multistage tumorigenesis]]
 +
 +
*[[Multitarget equation]]
 +
 +
*[[Multi-detector computed tomography]]
  
 
*[[Mutation component]]
 
*[[Mutation component]]
Line 609: Line 845:
  
 
=== <big><span id="N">N</span></big> ===
 
=== <big><span id="N">N</span></big> ===
 +
 +
*[[National radon survey]]
 +
 +
*[[National DRL]]
  
 
*[[Naturally occurring radioactive material]]
 
*[[Naturally occurring radioactive material]]
Line 619: Line 859:
  
 
*NHEJ (see [[Non-homologous end joining]])
 
*NHEJ (see [[Non-homologous end joining]])
 +
 +
*[[Noise]] (in imaging)
 +
 +
*[[Nominal value]]
  
 
*[[Nominal risk coefficient]]
 
*[[Nominal risk coefficient]]
Line 631: Line 875:
  
 
*[[Normal tissue complication probability]]
 
*[[Normal tissue complication probability]]
 +
 +
*[[Notification value]] (in CT)
 +
 +
*[[Nuclear medicine]]
  
 
*[[Nuclear track detectors]]
 
*[[Nuclear track detectors]]
  
 
=== <big><span id="O">O</span></big> ===
 
=== <big><span id="O">O</span></big> ===
 +
 +
*OAR (see [[Organ at risk]])
 +
 +
*[[Occupancy factor]]
  
 
*[[Occupational exposure]]
 
*[[Occupational exposure]]
 +
 +
*OEA (see [[Oxygen enhancement ratio]])
 +
 +
*[[OLINDA/EXM]]
  
 
*[[Oncogene]]
 
*[[Oncogene]]
 +
 +
*[[Operating management]]
 +
 +
*[[Operational quantity]]
  
 
*[[Optimisation]]
 
*[[Optimisation]]
 +
 +
*[[Optimisation of protection]]
 +
 +
*Organ absorbed dose (see [[Organ/tissue absorbed dose]])
 +
 +
*[[Organ at risk]]
 +
 +
*[[Organ dose equivalent]]
 +
 +
*[[Organ/tissue absorbed dose]]
 +
 +
*[[Other (systemic) tissues]]
  
 
*[[Orphan source]]
 
*[[Orphan source]]
  
 
*[[Oversight]]
 
*[[Oversight]]
 +
 +
*[[Oxygen enhancement ratio]]
  
 
=== <big><span id="P">P</span></big> ===
 
=== <big><span id="P">P</span></big> ===
 +
 +
*Particle fluence (see [[Fluence]])
 +
 +
*[[Particle transport]] (in biokinetics)
  
 
*[[Particle radiance]]
 
*[[Particle radiance]]
Line 655: Line 933:
  
 
*[[Pelagic]]
 
*[[Pelagic]]
 +
 +
*[[Pencil beam]]
  
 
*[[Percutaneous coronary intervention]]
 
*[[Percutaneous coronary intervention]]
  
 
*[[Pericarditis]]
 
*[[Pericarditis]]
 +
 +
*[[Personal dose equivalent]], H<sub>p</sub>(d)
 +
 +
*[[Phantom]]
  
 
*[[Pharynx]]
 
*[[Pharynx]]
 +
 +
*[[Pilomatricoma]]
  
 
*[[Planned exposure situation]]
 
*[[Planned exposure situation]]
Line 671: Line 957:
  
 
*[[Population risk]]
 
*[[Population risk]]
 +
 +
*[[Potential alpha energy concentration]]
  
 
*[[Potential exposure]]
 
*[[Potential exposure]]
 +
 +
*[[Potential recoverability correction factor]]
  
 
*[[Potentially lethal damage repair]]
 
*[[Potentially lethal damage repair]]
  
 
*[[Practical radiological protection culture]]
 
*[[Practical radiological protection culture]]
 +
 +
*[[Practice]]
 +
 +
*PRCF (see [[Potential recoverability correction factor]])
  
 
*[[Prevailing circumstances]]
 
*[[Prevailing circumstances]]
Line 685: Line 979:
  
 
*[[Principle of optimisation]]
 
*[[Principle of optimisation]]
 +
 +
*[[Principles of protection]]
  
 
*[[Procedural values]]
 
*[[Procedural values]]
Line 693: Line 989:
  
 
*[[Projected dose]]
 
*[[Projected dose]]
 +
 +
*[[Protection quantities]]
  
 
*[[Protection strategy]]
 
*[[Protection strategy]]
Line 707: Line 1,005:
  
 
*[[Qualified expert]]
 
*[[Qualified expert]]
 +
 +
*[[Quality control testing]] (x-ray equipment)
 +
 +
*[[Quality factor]], Q(L)
  
 
*[[Quasi-threshold dose]]
 
*[[Quasi-threshold dose]]
Line 724: Line 1,026:
 
*[[Radiation source]]
 
*[[Radiation source]]
  
−
*[[Radiation weighting factor]]
+
*[[Radiation weighting factor]], w<sub>R</sub>
 +
 
 +
*[[Radiation-induced second cancer]]
 +
 
 +
*[[Radiation-induced secondary malignancy]]
  
 
*[[Radiation worker]]
 
*[[Radiation worker]]
Line 733: Line 1,039:
  
 
*[[Radioactive substance]]
 
*[[Radioactive substance]]
 +
 +
*[[Radioactive waste]]
  
 
*[[Radioactivity]]
 
*[[Radioactivity]]
Line 739: Line 1,047:
  
 
*[[Radiographer]]
 
*[[Radiographer]]
 +
 +
*[[Radiological attack]]
  
 
*[[Radiological controlled area]]
 
*[[Radiological controlled area]]
Line 751: Line 1,061:
  
 
*[[Radiosensitivity, cellular]]
 
*[[Radiosensitivity, cellular]]
 +
 +
*[[Radon progeny]]
 +
 +
*[[Radon-prone area]]
  
 
*RAP (see [[Reference Animal and Plant]])
 
*RAP (see [[Reference Animal and Plant]])
 +
 +
*[[Ras]]
 +
 +
*[[Rb]]
  
 
*RBE (see [[Relative biological effectiveness]])
 
*RBE (see [[Relative biological effectiveness]])
Line 765: Line 1,083:
  
 
*[[Recovery (cellular or tissue)]]
 
*[[Recovery (cellular or tissue)]]
 +
 +
*[[Redox]]
 +
 +
*[[Reference air kerma]]
  
 
*[[Reference Animal and Plant]]
 
*[[Reference Animal and Plant]]
Line 771: Line 1,093:
  
 
*[[Reference biokinetic model]]
 
*[[Reference biokinetic model]]
 +
 +
*[[Referrer]]
 +
 +
*Reference female (see [[Reference Person]])
 +
 +
*[[Reference individual]]
  
 
*[[Reference level]]
 
*[[Reference level]]
 +
 +
*Reference male (see [[Reference Person]])
 +
 +
*[[Reference parameter value]]
 +
 +
*[[Reference Person]]
 +
 +
*[[Reference phantom]]
 +
 +
*[[Reference value]]
 +
 +
*[[Reference worker]]
 +
 +
*[[Region]]
 +
 +
*[[Regional diagnostic reference levels]]
 +
 +
*[[Registry]]
  
 
*REID (see [[Lifetime risk estimates]])
 
*REID (see [[Lifetime risk estimates]])
 +
 +
*[[Rigidity threshold]]
  
 
*[[Rehabilitation of living conditions]]
 
*[[Rehabilitation of living conditions]]
Line 783: Line 1,131:
  
 
*[[Relative risk]]
 
*[[Relative risk]]
 +
 +
*[[Relative survival]]
  
 
*[[Relocation]]
 
*[[Relocation]]
Line 801: Line 1,151:
  
 
*[[Respiratory protection]]
 
*[[Respiratory protection]]
 +
 +
*Response function (see [[Dose-response function]])
  
 
*[[Retrievability]]
 
*[[Retrievability]]
Line 819: Line 1,171:
  
 
*[[Risk model]]
 
*[[Risk model]]
 +
 +
*RISM (see [[Radiation-induced secondary malignancy]])
  
 
*Risk of exposure-induced death (see (see [[Lifetime risk estimates]])
 
*Risk of exposure-induced death (see (see [[Lifetime risk estimates]])
Line 829: Line 1,183:
  
 
=== <big><span id="S">S</span></big> ===
 
=== <big><span id="S">S</span></big> ===
 +
 +
*[[S coefficient (radiation weighted)]]
 +
 +
*SAF (see [[Specific absorbed fraction]])
  
 
*[[Safety case]]
 
*[[Safety case]]
 +
 +
*[[Safety]]
  
 
*[[Safety culture]]
 
*[[Safety culture]]
  
 
*[[Scintigraphy]]
 
*[[Scintigraphy]]
 +
 +
*[[Sealed source]]
 +
 +
*[[Secondary radiation]]
 +
 +
*[[Secretory cells]]
 +
 +
*[[Security]]
 +
 +
*[[Security screening]]
 +
 +
*SEE (see [[Specific effective energy]]]
  
 
*[[Self-help protection]]
 
*[[Self-help protection]]
Line 841: Line 1,213:
  
 
*[[Severe deterministic injury]]
 
*[[Severe deterministic injury]]
 +
 +
*[[Sheltering]]
 +
 +
*[[Shielding]]
 +
 +
*[[Sievert]] (Sv)
 +
 +
*[[Size-specific dose estimate]]
  
 
*SLDR (see [[Sublethal damage repair]])
 
*SLDR (see [[Sublethal damage repair]])
 +
 +
*[[Slice]] (in CT & CBCT)
  
 
*[[Slow repair]]
 
*[[Slow repair]]
 +
 +
*SOBP (see [[Spread-out Bragg peak]])
  
 
*[[Solar cosmic radiation]]
 
*[[Solar cosmic radiation]]
  
 
*[[Solar cycle]]
 
*[[Solar cycle]]
 +
 +
*[[Solar flare]]
  
 
*[[Solar particle event]]
 
*[[Solar particle event]]
Line 857: Line 1,243:
  
 
*Source (see [[Radiation source]])
 
*Source (see [[Radiation source]])
 +
 +
*[[Source region]]
  
 
*[[Source term]]
 
*[[Source term]]
  
 
*[[Source-related]]
 
*[[Source-related]]
 +
 +
*[[Source-related assessment]]
  
 
*[[South Atlantic anomaly]]  
 
*[[South Atlantic anomaly]]  
  
 
*[[Special (non-routine) monitoring]]
 
*[[Special (non-routine) monitoring]]
 +
 +
*[[Specific absorbed fraction]]
 +
 +
*[[Specific effective energy]]
 +
 +
*[[Spongiosa]]
  
 
*[[Spontaneous fission]]
 
*[[Spontaneous fission]]
 +
 +
*[[Spread-out Bragg peak]]
  
 
*[[Stakeholder]]
 
*[[Stakeholder]]
 +
 +
*[[Standard-size adult]]
 +
 +
*[[Stem cell]]
  
 
*[[Stenosis]]
 
*[[Stenosis]]
Line 881: Line 1,283:
  
 
*[[Substantial radiation dose level]]
 
*[[Substantial radiation dose level]]
 +
 +
*[[Superposition principle]] (in dosimetry)
  
 
*[[Supervised area]]
 
*[[Supervised area]]
 +
 +
*[[Surface contamination]]
  
 
*[[Systemic model]]
 
*[[Systemic model]]
  
 
=== <big><span id="T">T</span></big> ===
 
=== <big><span id="T">T</span></big> ===
−
 
  
 
*[[Tachycardia]]
 
*[[Tachycardia]]
Line 898: Line 1,303:
  
 
*[[Telangiectasia]]
 
*[[Telangiectasia]]
 +
 +
*[[Teratocarcinoma]]
 +
 +
*[[Thermodynamic diameter]]
 +
 +
*[[Thoracic airways]]
  
 
*[[Threshold dose for tissue reactions]]
 
*[[Threshold dose for tissue reactions]]
 +
 +
*[[Threshold level]]
 +
 +
*Tissue absorbed dose (see [[Organ/tissue absorbed dose]])
 +
 +
*[[Thoron progeny]]
  
 
*[[Thyroid blocking]]
 
*[[Thyroid blocking]]
  
 
*[[Time factor]]
 
*[[Time factor]]
 +
 +
*[[Time-resolved computed tomography]]
  
 
*[[Tissue equivalent material]]
 
*[[Tissue equivalent material]]
Line 912: Line 1,331:
  
 
*[[Tolerability]]
 
*[[Tolerability]]
 +
 +
*[[Tolerance dose]] (in Radiotherapy)
  
 
*[[Track structure]]
 
*[[Track structure]]
Line 926: Line 1,347:
  
 
*[[Translocation]]
 
*[[Translocation]]
 +
 +
*[[Transmission detection system]]
  
 
*[[Transparency]]
 
*[[Transparency]]
Line 934: Line 1,357:
  
 
*[[Trapped particles]]
 
*[[Trapped particles]]
 +
 +
*[[Treatment preparation in radiotherapy]]
 +
 +
*[[Trophic level]]
  
 
*[[Types of materials]]
 
*[[Types of materials]]
 +
 +
*[[Typical value]] (for DRL)
  
 
=== <big><span id="U">U</span></big> ===
 
=== <big><span id="U">U</span></big> ===
 +
 +
*[[Unattached fraction]]
  
 
*[[Unsealed source]]
 
*[[Unsealed source]]
 +
 +
*[[Upper reference levels]]
 +
 +
*[[Uptake]]
  
 
*[[Utilitarian ethics]]
 
*[[Utilitarian ethics]]
Line 950: Line 1,385:
  
 
*[[Virtue ethics]]
 
*[[Virtue ethics]]
 +
 +
*[[Voxel phantom]]
  
 
=== <big><span id="W">W</span></big> ===
 
=== <big><span id="W">W</span></big> ===
  
 
*[[Waste disposal]]
 
*[[Waste disposal]]
 +
 +
*[[Waste management]]
  
 
*[[Wisdom]]
 
*[[Wisdom]]
 +
 +
*WL (see [[Working level]])
 +
 +
*WLM (see [[Working level month]])
 +
 +
*[[Worker]]
 +
 +
*[[Working level]]
 +
 +
*[[Working level month]]
  
 
*w<sub>T</sub> (see [[Tissue weighting factor]])
 
*w<sub>T</sub> (see [[Tissue weighting factor]])

Latest revision as of 14:37, 3 October 2021

Glossary Header-left2.png

The ICRP Glossary collects ICRP’s definitive explanations of terms for current use. Some entries include historical descriptions to help readers better understand the term in a particular context.

It is a living document, updated regularly.

Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.

Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ...

0-9

A

B

C

D

  • Dose (of ionising radiation)

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

...

Retrieved from "http://icrpaedia.org/index.php?title=ICRP_Glossary&oldid=3345"